Anti-IgD monoclonal as novel treatment for human autoimmune diseases and pro-inflammatory conditions.
Skip to content
IMT is a private early-stage Australian biotechnology startup based in Sydney Australia that focuses on the clinical & commercial development of therapeutic anti-IgD monoclonal antibody (mAb) as a first-in-class disease-modifying mAb biologic for human autoimmune diseases, allergic conditions and chronic inflammations.
IgD Mab Technology (IMT) 